Delving into the Latest Updates on Tsumura USA, Inc. with Synapse

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of TU-100 as an Adjunct to an Enhanced Recovery After Surgery (ERAS) Protocol in Subjects Undergoing Bowel Resection

This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).

开始日期2021-07-29

申办/合作机构

Tsumura USA, Inc.

NCT02232893 / Completed临床2期

A Randomized, Double-Blinded, Placebo-Controlled Trial of TU-100 in Patients Undergoing Laparoscopic Colectomy

TU-100 is a gastrointestinal drug produced from the three botanical raw materials, Asian ginseng, Zanthoxylum fruit (Japanese pepper), and ginger, based on proprietary aqueous decoction and granulation technology. The aim of this study is to assess the effect of TU-100 on post-operative quality of life during the 4 week postoperative period after straight, hand-assisted, or robot-assisted laparoscopic colectomy. Optimal efficacy parameters for subsequent outcome studies also will be explored.

开始日期2014-09-01

申办/合作机构

Tsumura USA, Inc.

[+1]

NCT02074579 / Completed临床2期

A Phase 2, Single-center, Randomized, Double-Blinded, Placebo-Controlled Study on the Efficacy of Daikenchuto (TU 100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

The aim of this study is to assess the effect of orally administered TU-100 (5 g three times daily [TID]) as compared to placebo on abdominal bloating rating in female IBS patients.

开始日期2014-07-01

申办/合作机构

Tsumura USA, Inc.

[+1]

100 项与 Tsumura USA, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Tsumura USA, Inc. 相关的专利（医药）

登录后查看更多信息

100 项与 Tsumura USA, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Tsumura USA, Inc. 相关的转化医学

登录后查看更多信息